Lupin signs exclusive licensing agreement with Neopharmed for Gastroenterology Brand Plasil® in the Philippines and Brazil

Global pharma major Lupin Limited (Lupin) today announced that its subsidiaries in the Philippines (Multicare Pharmaceuticals) and Brazil (MedQuimica) have signed an exclusive licensing agreement with Neopharmed Gentili S.p.A, an Italian pharmaceutical company, for marketing and promotional rights for the Gastroenterology brand, Plasil® (metoclopramide), in their respective markets.

This agreement will enhance Lupin's gastroenterology portfolio and expand its presence in emerging markets. Neopharmed will oversee product supply in the Philippines, ensuring quality and compliance with global standards. In Brazil, production will be shifted to Medquimica's manufacturing facility.

"Our partnership with Neopharmed represents a significant milestone in Lupin's commitment to expand access to Plasil, one of the most potent anti-emetic treatments, across key emerging markets. Our extensive local presence, regulatory expertise, and strong commercial capabilities in the Philippines and Brazil, together with Neopharmed's distribution network and reach, will broaden patient access and deliver meaningful health outcomes," said Fabrice Egros, President of Corporate Development, Lupin.

"We are pleased to partner with Lupin to bring Plasil® to two strategic and rapidly growing markets, such as Brazil and the Philippines. This agreement reflects our commitment to expanding Neopharmed's international footprint, while leveraging Lupin's strong local presence to ensure that Plasil® is available to every patient in need," said Matteo Meazzini, Director of Business Development, Neopharmed Gentili.

Plasil® is widely acknowledged for its efficacy in treating nausea, vomiting, and motility disorders that affect millions of patients.

Shares of Lupin Limited was last trading in BSE at Rs. 2118.25 as compared to the previous close of Rs. 2113.15. The total number of shares traded during the day was 13995 in over 1743 trades.

The stock hit an intraday high of Rs. 2126.85 and intraday low of 2098.05. The net turnover during the day was Rs. 29586622.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals Philippines MulticarePharmaceuticals Brazil MedQuimica LicensingAgreement NeopharmedGentiliSpA Italy